Joel Linden

Joel Linden is the Chief Scientific Officer at Adovate, specializing in synthesizing novel adenosine receptor ligands as drug candidates. With a background in medicine, pharmacology, and nephrology, Joel has held various professorial positions at institutions such as the University of Virginia School of Medicine, University of California, San Diego, and University of Maryland School of Medicine. Additionally, Joel has experience as a scientific advisor at Clinical Data, Inc. and as the founder & Chief Science Officer at Adenosine Therapeutics. Joel holds a PhD in Pharmacology from the University of Virginia School of Medicine and a Bachelor of Science in Biomathematics, Bioinformatics, and Computational Biology from Brown University.